Stem cell transplantation timing from last chemotherapy affects lymphocyte collection

07-26-2006

The timing of stem cell transplantation from the last chemotherapy affects lymphocyte collection and survival in patients with non-Hodgkin lymphoma.

According to recent research published in the British Journal of Haematology, "Autograft absolute lymphocyte count (A-ALC) is a prognostic factor for survival in non-Hodgkin lymphoma (NHL) after autologous stem cell transplantation (ASCT). An A-ALC is dependent upon the preaphaeresis absolute lymphocyte count (PA-ALC) at the time of aphaeresis.

"It was hypothesized that the time interval from last chemotherapy (TILC) to aphaeresis affects PA-ALC. One hundred and sixty consecutive NHL patients who underwent ASCT at the Mayo Clinic between 1996 and 2001 were evaluated."

"A strong correlation between TILC and PA-ALC (r=0.67, p<0.0001) was identified. Higher PA-ALC was observed in TILC {{>=}}55 days compared with TILC <55 days [median: 7.0 vs. 3.8 x 109/L], p<0.0001)," S.G. Holtan and colleagues at the Mayo Clinic wrote.

"TILC as a continuous variable was identified as a prognostic factor for overall survival (OS) [hazard ratio (HR)=0.989, p<0.01] and progression-free survival (PFS) (HR=0.992, p<0.0492).

"Median OS and PFS were longer in the TILC {{>=}}55 days vs. TILC <55 days group (not reached vs. 21 months, p<0.0008; 76 vs. 9 months, p<0.0025, respectively)," researchers reported.

The authors concluded, "Multivariate analysis demonstrated TILC to be an independent prognostic indicator for OS and PFS. These findings suggest that the immune status of the host at the time of aphaeresis may predict survival after ASCT."

Holtan and colleagues published their study in British Journal of Haematology (Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. Br J Haematol, 2006;133(6):628-633).

For additional information, contact L.F. Porrata, Mayo Clinic, College Med, Dept. Internal Medicine, Division Hematology, 200 1st St. SW, Rochester, MN 55905, USA.

The publisher's contact information for the British Journal of Haematology is: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England.

Keywords: Rochester, Minnesota, United States, Absolute Lymphocyte Count, Autologous Stem Cell Transplantation, Non-Hodgkin Lymphoma, Prognostic Indicator.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.



Related Diseases: Non-Hodgkin Lymphoma (NHL)
Related Resources: Lymphoma Research Foundation, Lymphoma Information Network, Living with Lymphoma
Related Glossary Terms: Lymphocytes, Stem Cell Transplantation, Stem Cell Transplant, NHL, Autologous Transplant (Auto)
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Hana Biosciences' rALLy Clinical Trial of Marqibo Meets Response Criteria to Advance to Full Enrollment
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Acute Myeloid Leukemia (AML)
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
New leukemia signal could point way to better treatment, Stanford researchers find
Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
FDA Approves Vidaza Label Expansion
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
GlaxoSmithKline And Genmab Announce Positive Top-line Results In Ofatumumab Chronic Lymphocytic Leukaemia Pivotal Study
Sparing leukemia patients from unnecessary chemo
Chronic Myeloid Leukemia (CML)
Improved Survival in Pediatric Leukemia Following Unrelated Bone Marrow but not Peripheral Blood Stem Cell Transplantation
Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Targeted therapies for CML: practical considerations and comparisons
Hodgkin Lymphoma
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
September Is National Leukemia and Lymphoma Awareness Month
Nerve cancer mutations found
Autologous Stem Cell Transplantation Effective for Relapsed or Refractory Hodgkin’s Lymphoma
Multiple Myeloma
Thalomid® in Induction Improves Progression-free Survival in Elderly with Myeloma
The IMF says journal editorial documents dramatic increase in survival since the 1980s
FDA Approves Vidaza Label Expansion
Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment
B-MS boosts biologics pipeline with PDL BioPharma deal
Myelodysplastic Syndrome (MDS)
Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
FDA Approves Vidaza Label Expansion
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Non-Hodgkin Lymphoma (NHL)
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
September Is National Leukemia and Lymphoma Awareness Month
Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer